Apostolos C. C. Tsolakis, Thomas Zadrozny, Aristides Bakandritsos, Marianna Rosetti, Arben Merkoci, Vincent Bouchiat, Makis Angelakeris, Sandeep Kumar Kumar, Jean‐Jacques Toulmé, Aristotelis Folas, Felix Hempel, Chandan Singh, Alexey Tarasov, Despoina Batsouli, Spyros Tsiotos, Spyros N Yannopoulos, Diana Marcano, Ioanna Deligkiozi, Daniel Izquierdo Bote, María Begoña González García, Pablo Fanjul Bolado, Cristian Bosch Serrano
Abstract Two-dimensional materials (2MD) have emerged as a transformative platform for biomedical sensing owing to their unique properties. Over the past decade, 2DM, such as graphene and MXenes have enabled sensing concepts with the potential to surpass the sensitivity, speed, and miniaturization limits of conventional technologies. When combined with other innovative materials such as aptamers or magnetic nanoparticles (MNPs), a range of components can be developed. From electrochemical electrodes and field effect transistor channels to conductive inks and triboelectric nanogenerators, these components offer a variety of biomedical applications that have the potential to revolutionize healthcare. This Roadmap reviews the current state of 2DM-based biomedical sensing within four EU-funded Horizon Europe projects under the Graphene Flagship, identifies key scientific and technological barriers, and outlines priority research directions for the short (2027) and mid-term (2030) future. The analysis focuses on the materials, various components comprising these materials, and several biomedical applications that are currently being researched within the overall biomedical focus of the Graphene Flagship Initiative. By consolidating expert perspectives from the four consortia, this roadmap aims to guide coordinated efforts to accelerate the transition of 2DM from laboratory demonstrations to robust, scalable, and impactful biomedical sensing technologies.